Vicore Pharma - Interim report April-June 2023
Vicore Pharma - Interim report April-June 2023 Stockholm, August 24, 2023 - Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the second quarter 2023.Important ev...
Source: pharmiweb.com